CCG 224061
CCG 224061 is a G protein-coupled receptor kinase 2 (GRK2) inhibitor with a IC50 of 0.066 μM. CCG 224061 inhibits GRK activity in cardiomyocytes. CCG 224061 is applicable to research related to heart disease, heart failure, myocardial hypertrophy and hypertension.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2055990-82-2
- 分子式: C19H20FN3O
- 分子量:325.39
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
IC50 & Target
[1]|
GRK2 0.066 μM (IC50) |
体外実験
CCG 224061 (E18) potently and selectively inhibits GRK2 with an IC50 of 0.07 μM, while it shows weak inhibitory effects on GRK5 (IC50 12.8 μM) and GRK1 (IC50 65.7 μM)[1].
CCG 224061 (5 min) potently inhibits GRK2 (IC50 = 0.066 μM) and exhibits activity against GRK1 (IC50 = 6.4 μM), GRK5 (IC50 = 1.3 μM), PKA (IC50 = 3.1 μM) and ROCK1 (100% inhibition at 10 μM) in in vitro purified kinase assays[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
| Species | Dose | Route | AUC0-∞ |
|---|---|---|---|
| Mice[2] | 10 mg/kg | i.p. | 731 ng·h/mL |
化学情報
-
CAS 番号 2055990-82-2
-
分子量 325.39
-
分子式 C19H20FN3O
-
SMILES
C(OC=1C=C2C(=CC1)NN=C2)[C@H]3[C@@H](CCNC3)C4=CC=C(F)C=C4
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)